Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 392 |
| PDBID: | 2XV6 |
| Chains: | B_A |
| Organism: | Human immunodeficiency virus 1, Vicugna pacos |
| Method: | XRD |
| Resolution (Å): | 1.89 |
| Reference: | Not available or To be published |
| Antibody | |
| Antibody: | 9 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | HIV-1 capsid protein p24 |
| Antigen mutation: | No |
| Durg Target: | Q72497; P12497; P03367; P35963; P04587; P04585; P03366; P03369; P12499; |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >2XV6_B|Chain B, D|CAMELID VHH 9|VICUGNA PACOS (30538) MAQVQLVESGGGLVQAGGSLRLSCAASGSFFMSNVMAWYRQAPGKARELIAAIRGGDMSTVYDDSVKGRFTITRDDDKNILYLQMNDLKPEDTAMYYCKASGSSWGQGTQVTVSSHHHHHH |
Antigen
Chain: A
Mutation: NULL
| >2XV6_A|Chain A, C|CAPSID PROTEIN P24|HUMAN IMMUNODEFICIENCY VIRUS 1 (11676) SPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTACQG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: ASN32 VAL33 MET34 ALA35 TYR37 ALA44 ARG45 GLU46 LEU47 ILE48 ALA50 ILE51 SER56 THR57 VAL58 TYR59 ASP60 ASP61 LYS64 LYS93 ALA94 SER95 GLY96 SER101 TRP103 A: PRO147 THR148 SER149 ILE150 LEU151 ASP152 ARG154 LEU172 GLU175 GLN176 ALA177 SER178 GLU180 VAL181 TRP184 MET185 GLU187 THR188 LEU189 GLN192 ASN193 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
